Extra heart recruits for Mesoblast
Friday, 27 February, 2009
A good safety report has allowed recruitment to proceed of a further group of patients for a Phase II trial of Angioblast’s Revascor universal adult stem cell product.
Angioblast, the US-based sister company of Melbourne’s Mesoblast, is conducting a Phase II trial of Revascor in patients with congestive heart failure.
No adverse effects were recorded in the first 20 patients on a low dose of the product. Recruitment will now begin for another 20-person group to receive a higher dose.
The allogeneic stem cell product is being developed to reverse congestive heart failure by rebuilding blood vessels and heart muscle.
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
